$65.33▴ 6.59%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-16.45MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+106.9%year over year
Decelerating
Still growing fast, but the pace has been easing.
Leverage
Lowdebt to assets
Strong
Very low debt relative to its asset base.
More coming: dilution / share-count creep.
✦ The read
Tarsus Pharmaceuticals, Inc. is pre-profit. It is still burning cash while pre-profit. Still growing fast, but the pace has been easing. Very low debt relative to its asset base.
Key numbers
Valuation
EPS (TTM)$-1.13
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-9.0%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$535.08M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days1 article
0 bullish1 neutral0 bearish
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.